about
Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in developmentTemozolomide for aggressive ACTH pituitary tumors: failure of a second course of treatment.Capecitabine and temozolomide in grade 1/2 neuroendocrine tumors: a Spanish multicenter experience.Whole-exome sequencing identifies MDH2 as a new familial paraganglioma gene.Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors.PheoSeq: A Targeted Next-Generation Sequencing Assay for Pheochromocytoma and Paraganglioma Diagnostics.Translational research in neuroendocrine tumors: pitfalls and opportunities.Long-term treatment with pegvisomant for acromegaly: a 10-year experience.Recommendations on managing lenvatinib and everolimus in patients with advanced or metastatic renal cell carcinoma.Recommendations for somatic and germline genetic testing of single pheochromocytoma and paraganglioma based on findings from a series of 329 patients.Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC).No clinically significant valvular regurgitation in long-term cabergoline treatment for prolactinoma.Erratum to: Safety of long-term treatment with Pegvisomant: analysis of Spanish patients included in global ACROSTUDY.El año 2011 en NeuroendocrinologíaEscape and lipodystrophy in acromegaly during pegvisomant therapy, a retrospective multicentre Spanish studyResults of repeated transsphenoidal surgery in Cushing's disease. Long-term follow-upQ95409860
P50
Q28083433-5DD7E214-1F27-4202-A4E7-D2075B5EFAE0Q33427688-55AB30A7-31C4-4BF6-ABCC-25BDE4D6216DQ33436462-3D5326D3-AE95-45F8-A992-FCC6A4E06E82Q34466932-1CC7547D-46B0-4E3C-ACDD-FFAA34364A64Q35738251-B6B1AA10-E3C5-4055-A3A5-33F1925BFCFAQ38759395-1D9F9612-937D-431D-B1B8-6BD93A1AE2B3Q38958002-8D5B8659-AC4A-436B-BE30-DB53271541ACQ40216531-BB79D4C3-E5AE-4862-87B5-1D1AE100A969Q50049497-A4C425A1-3710-431B-97A7-75CA5AE0C364Q50438414-B5C4CB08-2848-4E58-98A2-666EFEBEC05CQ50541163-43298E38-94CB-4230-979B-64E1D287C5BEQ50971056-CF2F179D-E5D1-4331-A7F4-F9C4335D3B33Q54504621-0215B87A-E9C8-4977-A22C-88ECC6F0EC48Q60707236-2D486D41-E631-4A98-882E-9D7F189592FCQ62559156-D35E9EF4-7F2D-4ACE-B755-FA2C27BEBCD6Q86981047-B6359C08-77BD-4358-B0D4-6E94017E8025Q95409860-219AED3B-F48E-45BE-812E-7C4DE1EE675B
P50
description
onderzoeker
@nl
researcher ORCID id 0000-0001-6334-9072
@en
name
Javier Aller
@ast
Javier Aller
@en
Javier Aller
@es
Javier Aller
@nl
type
label
Javier Aller
@ast
Javier Aller
@en
Javier Aller
@es
Javier Aller
@nl
prefLabel
Javier Aller
@ast
Javier Aller
@en
Javier Aller
@es
Javier Aller
@nl
P106
P1153
18433600500
P21
P31
P496
0000-0001-6334-9072